REACH to review procedures as 2013 deadline looms

Published: 21-Oct-2011
Ingredients Regulatory

Will release proposals by June 2012


The European Commission is preparing to review the European Union’s (EU) chemical control system REACH, and will release its proposals by next June (2012).

These proposals will consider the operation of the system itself; whether it should be changed to avoid overlaps with other EU chemical legislation; and a special review of REACH assessments of chemicals used in small quantities.

Meanwhile, ECHA – in common with other EU agencies this year – has promised to make transparency and conflicts of interest a priority, adopting new guidelines and policies.

ECHA said new guidance, to be published soon, ‘demonstrates the importance of transparency and independence of decision-making’ at the agency. It will involve a new declaration of interest for ECHA employees, its management board and other agency bodies. An ethical committee will also be created.

The changes come as the agency has warned the pharmaceutical sector to prepare for the next key registration deadline under REACH and has launched a 'REACH 2013 – Act Now' campaign.

The deadline is 31 May, 2013, and covers companies manufacturing or importing chemicals in quantities of more than 100 tonnes a year.

See more

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

Read more
New certification allows accreditation without prior approval

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Subscribe now